William G Wierda, MD, PhD
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. EHA 2023;Abstract S145.
Fürstenau M et al. First-line venetoclax combinations in fit patients with CLL: 4-year follow-up and NGS-based MRD analysis from the phase 3 GAIA/CLL13 trial. ASH 2023;Abstract 635.
Langerbeins P et al. The CLL12 trial: Ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood 2022;139(2):177-87. Abstract
Riecke A et al. Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -Results from the GCLLSG CLL12 trial. ASH 2023;Abstract 199.
Sharman J et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN. ASH 2023;Abstract 636.
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. ASCO 2022;Abstract 7539.
Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: 5-year follow-up of ELEVATE-TN. EHA 2022;Abstract P666.
Tausch E et al. Genetic markers and front line FCR/BR vs. rve, gve and give treatment - Outcome results from the CLL13/GAIA trial. ASH 2022;Abstract 345.
Wiestner A et al. Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study. ASH 2023;Abstract 201.
Matthew S Davids, MD, MMSc
Barr PM et al. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study. ASCO 2023;Abstract 7535.
Eichhorst B et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med 2023;388(19):1739-54. Abstract
Hillmen P et al. Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: Report of the phase III UK NCRI FLAIR study. ASH 2023;Abstract 631.
Kim AI et al. Phase I safety and preliminary efficacy of acalabrutinib, venetoclax, and obinutuzumab (AVO) in patients with relapsed/refractory mantle cell lymphoma. ASH 2022;Abstract 3031.
Niemann CU et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24(12):1423-33. Abstract
Ryan CE et al. MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol 2022;18(33):3689-99. Abstract
Farrukh T Awan, MD
Bourrier N et al. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia. BMC Cancer 2022;22(1):148. Abstract
Brown JR et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388(4):319-32. Abstract
Eichhorst B et al. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial. EHA 2022;Abstract LB2365.
Seymour JF et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood 2023;142(8):687-99. Abstract
Shanafelt TD et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial. Blood 2022;140(2):112-20. Abstract
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. ASCO 2022;Abstract 7539.
Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: 5-year follow-up of ELEVATE-TN. EHA 2022;Abstract P666.
Tam CS et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial. Lancet Oncol 2022;23(8):1031-43. Abstract
Jennifer Woyach, MD
Brown JR et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319-32. Abstract
Ghia P et al. Acalabrutinib versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia: Final ASCEND trial results. Hemasphere 2022;6(12):e801. Abstract
Kater AP et al. Final 7-year follow up and retreatment substudy analysis of MURANO: Venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). EHA 2023;Abstract S201.
Mato AR et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389(1):33-44. Abstract
Seymour JF. CLL12: A positive answer to a poorly phrased question. Blood 2022;139(2):151-2. Abstract
Thompson PA, Siddiqi T. Treatment of Richter’s syndrome. Blood 2022;2022(1):329-36. Abstract
Weirda WG et al. Pirtobrutinib in Richter transformation: Updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN Study. ASH 2022;Abstract 1737.
Woyach J et al. Recurrent genomic alterations in the apoptotic machinery in patients with CLL treated with venetoclax monotherapy following treatment with BCRi. iwCLL 2023;Abstract 1553189.
Stephen J Schuster, MD
Abramson JS et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study. Blood 2023;141(14):1675-84. Abstract
Dubovsky JA et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013;122(15):2539-49. Abstract
Fowler NH et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nat Med 2022;28(2):325-32. Abstract
Fraietta JA et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 2016;127(9):1117-27. Abstract
Gill S et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv 2022;6(21):5774-85. Abstract
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91-103. Abstract
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract
Long M et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 2017;127(8):3052-64. Abstract
Melenhorst JJ et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 2022;602(7897):503-9. Abstract
Mhibik M et al. Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv 2023;7(15):4089-101. Abstract
Siddiqi T et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): A multicentre, open-label, single-arm, phase 1-2 study. Lancet 2023;402(10402):641-54. Abstract
Siddiqi T et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2022;139(12):1794-806. Abstract